# Citadel Advisors LLC

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/citadel-advisors-llc
Canonical HTML page: https://getyourbrief.com/entity/citadel-advisors-llc

## Timeline

- **2026-07-10**: Shares drop 1.8% — APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
- **2026-06-24**: Weiss Ratings reiterates sell — Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.
- **2026-05-07**: Q1 earnings beat — Apyx Medical reported Q1 EPS of -$0.05 vs -$0.11 expected and revenue of $12.49M vs $10.53M expected.
- **2026-04-26**: Wall Street Zen downgrades APYX — Wall Street Zen lowered Apyx Medical from a buy rating to a hold rating.

## Recent coverage (5 stories, network-wide)

### Renuvion Maker Apyx Drops 1.8% to $4.38 Despite Q1 Revenue Beat
2026-08-13 02:42:20 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
Full story: https://gethealthbrief.com/story/apyx-medical-revenue-beat-stock-drop-health

### Apyx Medical EPS Beats by $0.06, Stock Still Slides 1.8% to $4.38
2026-08-13 02:42:10 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Full story: https://getbiobrief.com/story/apyx-medical-q1-eps-beat-stock-slide-bio

### ENSC Shorts Up 619.9% at $0.30; FCUV Revenue $0.05M
2026-08-13 01:23:24 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Full story: https://gethealthbrief.com/story/ensc-shorts-up-619-9-fcuv-revenue-0-05m

### SCYX Short Interest Plunges 87.6% as ENSC Spikes 619.9%
2026-08-13 01:23:11 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Full story: https://getbiobrief.com/story/scyx-short-interest-plunges-87-6-ensc-spikes-619-9

### Entera Bio Down 0.6% as $9.00 Analyst Target Highlights Split
2026-08-12 16:26:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Full story: https://getbiobrief.com/story/entera-bio-down-06-analyst-target-9

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.